Sunday, December 22, 2024
HomeTagsNVL-520

NVL-520

Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, announced that the first patient has been dosed...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics